# US 12,758,679 B2 · Composition for treating wound comprising dermal tissue-derived extracellular matrix and method for preparing same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,758,679 B2 - Document ID: US12758679B2 - Status: Granted - Kind: B2 - Application number: 18/268,590 - Filed: 2020-12-21 - Published: 2024-02-08 - Granted: 2026-10-13 - Earliest claimed: 2020-12-21 - Assignees: L&C Bio Co., Ltd. - Applicants: L&C Bio Co., Ltd. - Inventors: Sang Chul Kim; Kee Won Lee; Hyung Gu Kim; Whan Chul Lee - Web page: https://patentgrep.com/patent/US12758679B2 ## CPC - A61L 26/0057: {Ingredients of undetermined constitution or reaction products thereof} - A61L 26/0023: {Polysaccharides} - A61L 2300/64: Animal cells - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) ## Abstract Disclosed is a composition for treating a wound including a dermis-derived extracellular matrix and a method for preparing the composition. By using the composition for treating a wound according to the present invention, the composition can be applied to wounds of various sizes and depths by increasing the viscosity of the composition, the composition is well coagulated without falling off for a certain period of time after application to a wound surface, and the composition can promote recovery. ## Claims ### Claim 1 A composition for treating wounds consisting essentially of: a first biopolymer crosslinked to a dermal extracellular matrix (ECM); and a second biopolymer; wherein: the first biopolymer is selected from the group consisting of collagen, hyaluronic acid, chitosan, carboxymethylcellulose, alginate, gelatin, and hydroxyapatite; the second biopolymer is selected from the group consisting of collagen, hyaluronic acid, chitosan, carboxymethylcellulose, alginate, gelatin, and hydroxyapatite, or the second biopolymer is a crosslinked product of a biopolymer selected from the group consisting of collagen, hyaluronic acid, chitosan, carboxymethylcellulose, alginate, gelatin, and hydroxyapatite; the content of the first biopolymer crosslinked to a dermal extracellular matrix is 5 parts to 40 parts by weight with respect to the total weight of the composition, and the composition for treating wounds has a complex viscosity of 1,000 Pa S to 10,000 Pa S; wherein the first biopolymer crosslinked to a dermal extracellular matrix is prepared by: i) removing a lipid component from skin tissue of a human; ii) preparing dermal ECM by removing cells from adipose tissue from which the lipid component is removed; iii) freeze-drying the adipose tissue from which cells are removed; iv) powdering the freeze-dried lyophilizate; v) preparing a first biopolymer crosslinked to a dermal extracellular matrix by crosslinking the powdered dermal ECM and the first biopolymer; vi) freeze-drying the crosslinked dermal ECM-first biopolymer product; and vii) powdering the freeze-dried lyophilizate; viii) preparing the second biopolymer by crosslinking the biopolymer using a crosslinking agent; and drying the resulting crosslinked product, wherein the crosslinking agent of the first biopolymer and the second biopolymer is selected from the group consisting of 1,4-butandiol diglycidyl ether (BDDE), ethylene glycol diglycidyl ether (EGDGE), 1,6-hexanediol diglycidyl ether, propylene glycol diglycidyl ether, polypropylene glycol diglycidyl ether, polytetramethylene glycol diglycidyl ether, neopentyl glycol diglycidyl ether, polyglycerol polyglycidyl ether, diglycerol polyglycidyl ether, glycerol polyglycidyl ether, tri-methylpropane polyglycidyl ether, 1,2-(bis(2,3-epoxypropoxy)ethylene, pentaerythritol polyglycidyl ether, and sorbitol polyglycidyl ether; and ix) mixing the crosslinked dermal extracellular matrix (ECM)-first biopolymer product and the second crosslinked biopolymer. ### Claim 2 (depends on 1) The composition of claim 1, wherein the dermal ECM is delipidated and decellularized skin-derived dermal tissue. ### Claim 3 (depends on 1) The composition of claim 1, wherein the crosslinked dermal ECM-biopolymer product has an average particle diameter of 100 to 800 μm. ### Claim 4 (depends on 1) The composition of claim 1, wherein the content of the second biopolymer is 60 parts to 95 parts by weight with respect to the total weight of the composition. ### Claim 5 (depends on 1) The composition of claim 1, wherein i) is performed using a delipidation solution, and the delipidation solution is a polar solvent, a non-polar solvent, or a mixed solvent thereof. ### Claim 6 (depends on 1) The composition of claim 1, wherein ii) is performed using a decellularization solution, and the decellularization solution consists essentially of a salt selected from the group consisting of sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium carbonate, magnesium hydroxide, calcium hydroxide, ammonia, sodium deoxycholate (SDC), sodium dodecyl sulfate (SDS), alkylbenzene sulfonate (ALS), alcohol ether sulfates (AES), sodium lauryl sulfate (SLS), and polyethylene glycol (PEG). ### Claim 7 (depends on 1) The composition of claim 1, wherein v) is performed in the presence of a crosslinking agent, and the crosslinking agent is selected from the group consisting of 1,4-butandiol diglycidyl ether (BDDE), ethylene glycol diglycidyl ether (EGDGE), 1,6-hexanediol diglycidyl ether, propylene glycol diglycidyl ether, polypropylene glycol diglycidyl ether, polytetramethylene glycol diglycidyl ether, neopentyl glycol diglycidyl ether, polyglycerol polyglycidyl ether, diglycerol polyglycidyl ether, glycerol polyglycidyl ether, tri-methylpropane polyglycidyl ether, 1,2-(bis(2,3-epoxypropoxy)ethylene, pentaerythritol polyglycidyl ether, and sorbitol polyglycidyl ether. ### Claim 8 (depends on 7) The composition of claim 7, wherein the content of the crosslinking agent is 0.5 to 10 parts by weight with respect to the weight of the dermal ECM. ### Claim 9 (depends on 1) The composition of claim 1, further consisting essentially of sterilizing the resulting mixture of the crosslinked dermal extracellular matrix (ECM)-first biopolymer product and the second crosslinked biopolymer.